Country: United Kingdom
Language: English
Source: myHealthbox
Naproxen
Roche Products Limited
M01AE02
Naproxen
250mg
Gastro-resistant tablets
Oral use
Blister containing 56 tablets
POM - Prescription Only Medicine
Roche Products Limited
Anti-inflammatory and antirheumatic products, non-steroids
it is indicated in adults for the treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute musculoskeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhoea.
Authorised
1996-05-31
_1 _ _ _ uk-pl-naprosyn-ec-clean-150508-250-375-500mg-tabs_ _ PACKAGE LEAFLET: INFORMATION FOR THE PATIENT UK NAPROSYN® EC 250 MG, 375 MG AND 500 MG GASTRO-RESISTANT TABLETS ROCHE Naproxen READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. · Keep this leaflet. You may need to read it again. · If you have any further questions, ask your doctor or pharmacist. · This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. · If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Naprosyn EC is and what it is used for 2. What you need to know before you take Naprosyn EC 3. How to take Naprosyn EC 4. Possible side effects 5. How to store Naprosyn EC 6. Contents of the pack and other information 1. What Naprosyn EC is and what it is used for Naprosyn EC contains a medicine called naproxen. This is a ‘Non Steroidal Anti Inflammatory Drug’ or NSAID. Naprosyn EC can lessen pain, swelling, redness and heat (inflammation) and is used to treat adults for: · Problems with your muscles, joints and tendons, like strains, back pain, ankylosing spondylitis (pain and stiffness in the neck and back) or arthritis. · Women, while having period pain. 2. What you need to know before you take Naprosyn EC DO NOT TAKE NAPROSYN EC IF YOU ARE ALLERGIC (HYPERSENSITIVE) TO: · Naproxen, naproxen sodium or any of the other ingredients of Naprosyn EC (listed in section 6 Read the complete document
Naprosyn 250mg Tablets Summary of Product Characteristics Updated 02Jun2015 | Roche Products Limited 1. Name of the medicinal product Naprosyn 250mg Tablets 2. Qualitative and quantitative composition _Naprosyn 250mg Tablets_: Each tablet contains 250mg naproxen For full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet. _Naprosyn 250mg Tablets:_ Round, yellow uncoated tablet embossed “NPR LE 250” on one face and with a breakline on the other. 4. Clinical particulars 4.1 Therapeutic indications _Adults:_ Treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculoskeletal disorders and dysmenorrhoea. _Children:_ Juvenile rheumatoid arthritis 4.2 Posology and method of administration _Posology_ Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). _Adults_ _Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis_ 500mg to 1g taken in 2 doses at 12hour intervals or alternatively, as a single administration. In the following cases a loading dose of 750mg or 1g per day for the acute phase is recommended: a) In patients reporting severe nighttime pain/or morning stiffness. b) In patients being switched to Naprosyn from a high dose of another antirheumatic compound. c) In osteoarthrosis where pain is the predominant symptom. _Acute gout_ 750mg at once then 250mg every 8 hours until the attack has passed. _Acute musculoskeletal disorders and dysmenorrhoea_ 500mg initially followed by 250mg at 6 8 hour intervals as needed, with a maximum daily dose after the first day of 1250mg. _Older people_ Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction Read the complete document